Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has received an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $197.00.

KRYS has been the subject of several analyst reports. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup increased their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Evercore ISI upped their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th.

Krystal Biotech Trading Down 1.9 %

Shares of NASDAQ KRYS opened at $195.87 on Tuesday. Krystal Biotech has a 12-month low of $95.02 and a 12-month high of $219.34. The company has a market cap of $5.63 billion, a price-to-earnings ratio of 110.66 and a beta of 0.82. The stock’s 50 day simple moving average is $181.29 and its 200 day simple moving average is $180.86.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.67) earnings per share. As a group, equities analysts forecast that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

Hedge funds have recently modified their holdings of the business. Scout Investments Inc. acquired a new position in Krystal Biotech during the first quarter valued at $8,976,000. Sei Investments Co. lifted its position in shares of Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after purchasing an additional 18,968 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares during the period. Shaker Investments LLC OH purchased a new position in Krystal Biotech during the third quarter valued at approximately $532,000. Finally, Amalgamated Bank increased its stake in Krystal Biotech by 937.9% in the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock valued at $1,391,000 after buying an additional 6,847 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).